Remove 2019 Remove Diabetes Remove Labelling
article thumbnail

Semaglutide could provide novel dual benefit in diabetes and kidney disease

European Pharmaceutical Review

“Approximately 40 percent of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.”

article thumbnail

Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label

pharmaphorum

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. Invokana was the first mover among the SGLT2 drugs in the kidney area, winning FDA approval towards the end of 2019 for diabetic kidney disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SGLT-2 Inhibitors

RX Note

Introduction The treatment approach for type 2 diabetes mellitus has undergo a shift from the traditional glucose-centric approach to the new cardiorenal-metabolic approach. This change emphasizes a comprehensive approach for reducing the risk of diabetes-related complications.

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

pharmaphorum

The approval comes a few weeks after the biosimilar was cleared for marketing in the EU with a broader label, as it also includes diabetic macular oedema (DMO), another of Lucentis’ approved indications. Sales reached a peak in 2019, when Roche booked $1.8 billion in sales from the drug while Novartis made $2.1

article thumbnail

Novo Nordisk gets NICE okay for obesity drug Wegovy

pharmaphorum

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. The 2019 Health Survey for England estimated 28% of adults in England were obese and a further 36% were overweight, according to NICE.

Labelling 105
article thumbnail

ESC22: AstraZeneca’s Farxiga DELIVERs in heart failure

pharmaphorum

Farxiga – known as Forxiga in some markets – has been beating a trail for the SLGT2 inhibitor class in heart failure, extending their use beyond diabetes. Novartis’ blockbuster Entresto (sacubitril/valsartan) has also been approved in the US for both HFrEF and HFpEF, but so far has not had its labelling extended beyond HFrEF in the EU.